Here’s Mesh Bio! They’re a Singapore-based digital health startup that uses predictive analysis to improve chronic disease management. Now, they just raised a $3.5M Series A.

Investor check. East Ventures led the round, while Elev8, SEEDS Capital, and existing investors also joined in.

• FYI. East Ventures launched a $30M healthtech fund last year.
• Oh, and Mesh Bio raised a $1.8M seed in October 2021.

‍

☝️ First things first

According to the WHO, 9M people die every year of chronic (aka non-communicable) diseases in SEA. 

• Examples of chronic diseases include cardiovascular diseases, cancer, diabetes, kidney diseases,  and chronic respiratory diseases.
• But early detection is key—and that’s where Mesh Bio comes in.

‍

🫀The ABCs of Mesh Bio

Mesh Bio develops digital solutions that improve health screening and chronic disease management.

• Their main product DARA® summarizes key findings from a patient’s medical data to create a visual report for doctors fast.
• Doctors can identify risk trends and provide actionable lifestyle recommendations!

Something new? They also offer HealthVector® Diabetes, a software that provides an estimate of the 3-year-risk for chronic kidney disease stage 3A and above in adults diagnosed with Type 2 diabetes mellitus.

• The program creates a visual representation of the patient (digital twin) from patient data and other factors to get insight into the “expected behavior of the physical twin”.

‍

👬 Where to next? 

They’ll use the $$$ to offer their digital twin solutions to healthcare providers and accelerate the deployment of their tech across Hong Kong and SEA. 

• Where, exactly? They’ll start mainly in Indonesia and the Philippines.